
Opinion|Videos|September 17, 2024
Navigating the Safety Profile of Ruxolitinib in cGVHD
Panelists discuss how to effectively manage the safety profile of ruxolitinib when used in the treatment of chronic graft-versus-host disease, addressing potential adverse effects and monitoring strategies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































